In the present work, we report compilation and analysis of 245 drugs, including small and
macromolecules approved by the US FDA from 2015 until June 2020. Nearly 29% of the …

Computer-aided drug design (CADD) is an emerging field that has drawn a lot of interest
because of its potential to expedite and lower the cost of the drug development process …

Dry eye disease (DED) is a frequently observed eye complaint, which has recently attracted
considerable research interest. Conventional therapy for DED involves the use of artificial …

Integrins are transmembrane receptors that possess distinct ligand-binding specificities in
the extracellular domain and signaling properties in the cytoplasmic domain. While most …

Dry eye disease (DED) is a multifactorial disease of the ocular surface and tear film that has
gained awareness as a public health problem. Characteristics of DED include tear film …

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19
respiratory disease pandemic utilizes unique 2′-o-methyltransferase (2′-O-MTase) …

Neuropathic pain is caused by a primary lesion or dysfunction of the nervous system and
can occur in the cornea. However, neuropathic corneal pain (NCP) is currently an ill-defined …

Mucins are key actors in tear film quality and tear film stability. Alteration of membrane-
bound mucin expression on corneal and conjunctival epithelial cells and/or gel-forming …

Cequa®, a unique and first-in-class preservative free cyclosporine-A (CsA) nanomicellar
topical formulation was recently approved by US FDA for treatment of dry eye disease or …

The ocular drug discovery field has evidenced significant advancement in the past decade.
The FDA approvals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet …